Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
about
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disordersFlupenthixol versus placebo for schizophreniaFlupenthixol versus placebo for schizophreniaAmisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivoThe use of amisulpride in the treatment of acute psychosisThe effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyDipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.Addressing missing outcome data in meta-analysis.Amisulpride for schizophrenia.A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medicationsWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Safety and tolerability of antipsychotics: focus on amisulpride.Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences.Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues.Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorderIs the superior efficacy of new generation antipsychotics an artifact of LOCF?Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresInhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.Update on the management of symptoms in schizophrenia: focus on amisulpride.Accounting for uncertainty due to 'last observation carried forward' outcome imputation in a meta-analysis model.Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions.Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?Clinical advantages of amisulpride in the treatment of acute schizophrenia.Prolactin secretion is not a core dimension of "atypicality".Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems.Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers.Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.Efflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity
P2860
Q24194034-402B6147-EB70-4B5D-B100-FB70E6854A98Q24200708-53294575-36F4-4120-9344-1264E509FAEDQ24202853-5ADBEFD9-8D8C-4F74-99E8-C536888DCB12Q24647996-6F612A98-3DCD-4DD1-93A3-CA6F6E7CC3D9Q24683055-4E26C94D-1908-46BD-AA26-A07782D1CB31Q24800019-6EE95B16-D89B-400D-8974-525E9920B95FQ30438924-8925E244-D403-4D8D-8639-5A7DC1C983C6Q30835835-60B64EBB-45EE-45D4-955C-0859953F1C3AQ31083696-4CA972A8-7613-4A4F-AD67-3E11A795A8E7Q31131634-E61C848F-B0A4-4527-A6D3-F5C0B65F5F6FQ33223628-6E0CE3CF-2182-4832-BF87-5AEA26DFD7E6Q34006864-A304D5EC-E7D8-4807-8BF9-15C9C2623196Q34640811-0550C64D-EA8D-4242-9928-A4881A27B394Q35026487-F281AC23-DC64-4EE5-9520-57144EF736CFQ35073807-2BEE786C-78F3-44B3-BCBA-5B233AE75726Q36307088-E22C0726-7438-421B-87CC-C4A3576BA41FQ36836740-DAC21020-C698-4511-AF4D-05BB04EF07CDQ37076000-5F6B1459-24EA-4B49-8127-F820226531EFQ37227479-A04F168A-2049-4F25-A453-ADC4C6E2F58AQ38056146-4CE0D3A0-A7A9-41C7-9321-AD52034D7717Q41529086-4CC7DE74-92BD-4E4B-85B8-8B7BCAE65C6EQ41708693-457E1BF0-2029-44B6-A765-7C43E199B9BAQ43605913-E7F9F4C4-054B-4129-AAC2-35FF5E0F0319Q43789375-04124180-D6AF-485F-81F6-2ECCAC0A07F0Q43861966-F5C9A3A6-BB48-4D84-A8EF-ADC420C7753EQ44078942-FF22E911-F595-4078-9088-0142B4E96BFDQ44348745-848D3F2B-4B9D-40FF-9663-3659BA093057Q46886092-E24085F6-63FD-4181-B1E5-9F398D2B3587Q48381074-C80D7702-71C1-4DB1-A2DB-867C146093CBQ49058929-50DD4BB7-60AF-43A3-96BF-F69A5FA463B6Q50930340-57DF0DE0-4BDE-44FD-A421-4FDCD856BC85Q57656351-604B3BF4-57DD-4D54-816E-F02B2485BE6C
P2860
Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@en
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@nl
type
label
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@en
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@nl
prefLabel
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@en
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@nl
P2093
P356
P1433
P1476
Amisulpride versus flupentixol ...... . The Amisulpride Study Group.
@en
P2093
Schröder J
P2888
P304
P356
10.1007/S002130050614
P577
1998-06-01T00:00:00Z